

AAPS Workshop on Streamlining the CMC Regulatory Process for NDAs and ANDAs

Co-Sponsored with FDA

June 11-13, 2001 • Hyatt Regency Washington On Capitol Hill • Washington, DC



American Association of
Pharmaceutical Scientists

2107 Wilson Blvd., Suite 700
Arlington, VA 22201-3046, USA

Presorted
First Class
US Postage
PAID
Washington, DC
Permit No. 1914

Register by April 27 and Save!!

AAPS WORKSHOP

**Streamlining
the CMC
Regulatory
Process**

**Regulatory
Process**

**NDAs
ANDAs**

**Hyatt Regency Washington
On Capitol Hill**



aaps

American Association of
Pharmaceutical Scientists

Review the FDA categorization of post-approval changes as major, moderate or minor as reflected in the November, 1999 guidance on *Changes to An Approved NDA or ANDA*.

Discuss industry experience in and perspective on using the guidance.

Identify parts of the guidance that may warrant revision.

Provide a forum to discuss a new initiative under investigation by FDA which, for specific drugs, will:

Reduce the CMC information and data to be included in original ANDAs

Eliminate many NDA/ANDA manufacturing supplements

Reduce the CMC information and data included in NDA/ANDA manufacturing supplements

Develop scientific, risk-based criteria that could be used to identify drug substances and products that would be eligible for the new initiative.

Prepare a summary report that can be considered by FDA when revising the guidance on *Changes to an Approved NDA or ANDA* and in developing the guidance for the new initiative.

Planning Committee

Preliminary Program

Sunday, June 10

5:00 pm - 7:00 pm
REGISTRATION

Monday, June 11

7:00 am - 5:15 pm
REGISTRATION

8:00 am - 12:00 pm
Changes to an Approved NDA or ANDA

Moderators

Yuan-Yuan Chiu, Ph.D.
Tobias Massa, Ph.D.

8:00 am - 8:20 am
Welcoming Remarks

Yuan-Yuan Chiu, Ph.D.
Food and Drug Administration
Tobias Massa, Ph.D.

8:20 am - 8:40 am
Background/History

Food and Drug Administration
Nancy Sager

8:40 am - 9:05 am
Components and Composition/
Manufacturing Site Changes

Food and Drug Administration
Rashmikan Patel, Ph.D.

9:05 am - 9:35 am
Manufacturing Process Changes

Food and Drug Administration
Frank Holcombe, Ph.D.

9:35 am - 10:00 am
Tests and Acceptance Criteria
Changes

Food and Drug Administration
John Simmons, Ph.D.

Acronym Key

ANDA: Approved New Drug
Applications

CMC: Chemistry and Manufacturing
Controls

FDA: Food and Drug Administration
NDA: New Drug Application

Monday, June 11 (Continued)

10:00 am - 10:30 am
BREAK

10:30 am - 10:50 am
Labeling, Miscellaneous and
Multiple Changes

Food and Drug Administration
Florence Fang

10:50 am - 11:20 am
Sterile Drug Substances/Drug
Product Changes

Food and Drug Administration
Peter Cooney, Ph.D.

11:20 am - 11:40 am
PhRMA Industry Perspective

David Miner, Ph.D.
Eli Lilly and Company

11:40 am - 12:00 pm
Generic Industry Perspective

Christine A. Mundkur
Barr Laboratories, Inc.

12:00 pm - 1:00 pm
LUNCH (Complimentary to all registrants)

1:00 pm - 2:15 pm
CONCURRENT BREAKOUT SESSIONS
(Please select one)

A: Sterile Drug Substances/Drug
Products

B: Manufacturing Process

C: Components and Composition/
Manufacturing Site

D: Tests and Acceptance Criteria

E: Labeling, Miscellaneous and
Multiple

2:25 pm - 3:40 pm
CONCURRENT BREAKOUT SESSIONS
Repeated

3:40 pm - 4:00 pm
BREAK

4:00 pm - 5:15 pm
CONCURRENT BREAKOUT SESSIONS
Repeated

5:15 pm - 6:15 pm
RECEPTION

